News

We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.

Media releases

PolyPeptide announces results of the annual General Meeting 2023

12 Apr 2023 - Baar, 12 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), today announced that […]

Read more
Expert views

Green Chemistry Articles of Interest to the Pharmaceutical Industry

4 Apr 2023 - Bryan, M. C.; Dalton, C.; Díaz-Rodríguez, A.; Doerfler, J.; Engl, O. D.; Molina, A. G.; Harawa, V.; Kelly, C. B.; Li, W.; Munday, R. H.; Pawlas, […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO

3 Apr 2023 - Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of […]

Read more
Expert views

Developing the Toolbox for Sustainable Peptide Manufacturing

24 Mar 2023 - The need for sustainable manufacturing practices is a major challenge for the worldwide industry, and the pharma world is increasingly engaged in this important green transformation. […]

Read more
Expert views

Overcoming Oligonucleotide Manufacturing Challenges

24 Mar 2023 - The Oligonucleotide CMO industry faces a number of challenges – Demand out pacing capacity for manufacturing, available expertise, high solvent and waste usage to name a […]

Read more
Expert views

Chemical strategies in extending half-lives of therapeutic peptides

24 Mar 2023 - Therapeutic peptides have been proven to be very effective in treating critical human diseases. Their number on the pharmaceutical market has significantly increased over the past […]

Read more
Media releases

PolyPeptide publishes invitation to the annual General Meeting 2023

22 Mar 2023 - Baar, 22 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), published today the […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023

14 Mar 2023 - Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its results for […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

CEO of PolyPeptide resigns

30 Jan 2023 - Baar, 30 January 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the resignation by […]

Read more